An open-label, phase I, dose-escalation study of tumor necrosis factor-α (TNFerade™ biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors

Human Gene Therapy

Volumn 12, Issue 9, 2001, Pages 1109-1131

  Sharma, Anand ^a   Mani, Sridhar ^a   Hanna, Nader ^a  

^a NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TNFERADE;

ARTICLE; CLINICAL PROTOCOL; DRUG ADMINISTRATION; DRUG SURVEILLANCE PROGRAM; FEMALE; GENE TRANSFER; GENETICS; HUMAN; LEGAL ASPECT; MALE; METASTASIS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; STANDARD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG QUALITY; DRUG SAFETY; MEDICAL ETHICS; QUALITY CONTROL; RISK ASSESSMENT; SIDE EFFECT; SOLID TUMOR; STATISTICAL ANALYSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CLINICAL PROTOCOLS; CLINICAL TRIALS, PHASE I; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE TRANSFER TECHNIQUES; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASMS; PATIENT SELECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034926709     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303401750214320     Document Type: Article

References (22)

1. Adenovirus-mediated in vivo transfer
2. Tumor necrosis factor (TNF)
3. Endothelial leucolyte adhesion molecule 1: An inducible receptor for neutrophils related to complement regulatory proteins and lectins
4. TNF modulates endothelial properties by decreasing cAMP
5. An endotoxin induced serum factor that causes necrosis of tumors
6. Recombinant human tumor necrosis factor: Effects on proliferation of normal and transformed cells in vitro
7. Intracellular hydroxyl radical production induced by recombinant human tumor necrosis factor
8. Cytotoxic mechanism of tumor necrosis factor alpha
9. The interaction between recombinant human tumor necrosis factor and radiation in 13 human tumor cell lines
10. Phase I dose-escalation study of TNF-α and concomitant radiation therapy
11. Use of tumor necrosis factor in isolated hepatic perfusion
12. High-dose recombinant tumor necrosis factor alpha in combination with interferon-gamma and melphalan in isolated perfusion of the limbs for melanoma and sarcoma
13. In transit metastases of malignant melanoma treated by high dose rTNFα in combination with interferon gamma and melphalan in isolated perfusion
14. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion using melphalan
15. Isolated hepatic perfusion with tumor necrosis factor α and melphalan: Experimental studies in pigs and phase I data from humans
16. Isolated hepatic perfusion of tumor necrosis factor and melphalan for unresectable cancers confined to the liver
17. Spatial and temporal control of gene therapy using ionizing radiation
18. Tumor necrosis tumor factor α (TNFα) gene therapy targeted by ionizing radiation selectively damages tumor vasculature
19. Adenoviral TNF-α gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft
20. Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer
21. Characterization of AdEGR.TNF 11D toxicity